Abstract
Abstract
Findings from the phase I/IIa trial of AZD5305, a next-generation, highly selective PARP1 inhibitor, indicate that the drug is better tolerated in patients with ovarian, HER2-negative breast, pancreatic, and prostate cancers with BRCA1/2, PALB2, and RAD51C mutations compared with first-generation PARP inhibitors. In addition, 25% of 40 evaluable patients had a partial response.
Publisher
American Association for Cancer Research (AACR)
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献